For instance, results of a phase III trial in advanced/metastatic HER2-low BC (NCT03734029/DESTINY-Breast04) are awaited and NCT04553770 clinical trial in HR+ HER2-low early BC is currently recruiting patients to neoadjuvant trastuzumab-deruxtecan (± anastrozole) with pCR for the primary endpoint. Here, ERBB2 is linked to breast cancer.